Apelin-APLNR pathway emerges as critical endothelial regulator and therapeutic target across vascular, inflammatory diseases
Background
The apelinergic system, comprising Apelin, Elabela, and their shared receptor APLNR, is crucial for vascular development and endothelial homeostasis. Current standard-of-care often struggles with the complex interplay of endothelial dysfunction in conditions like hypertension, cardiac remodeling, and pulmonary vascular injury. This pathway integrates developmental cues, mechanical forces, hypoxia, and inflammatory signals, making it a compelling target for restoring endothelial integrity and mitigating damage in various cardiovascular, pulmonary, and inflammatory diseases.
Study Design
This review synthesizes current literature on the apelinergic system, focusing on the ligands Apelin and Elabela and their shared receptor APLNR. It examines evidence across various stages of development, physiological functions, and pathological conditions, specifically from an endothelial cell perspective. The authors compiled findings regarding APLNR expression, the role of Apelin and Elabela in angiogenic patterning, vascular stability, and tissue adaptation to stress, as well as their involvement in disease states and therapeutic potential.
Results
The review highlights APLNR as a G protein-coupled receptor highly enriched in endothelial cells across organs, integrating diverse signals. Apelin and Elabela are critical for guiding angiogenic patterning during cardiac, pulmonary, and retinal development. In adulthood, these peptides support endothelial nitric oxide production, vascular stability, and tissue adaptation to stress. Pathological conditions underscore the pathway's importance; reduced Apelin or altered APLNR expression contributes to hypertension, cardiac remodeling, pulmonary vascular injury, and immune-driven inflammation. Conversely, restoring apelinergic signaling improves endothelial barrier function, limits leukocyte recruitment, and mitigates fibrotic and ischemic damage. This includes improvements observed in experimental models of autoimmune encephalomyelitis and acute lung injury. The therapeutic interest is further bolstered by the development of stabilized Apelin analogs and small-molecule APLNR agonists with improved pharmacokinetics. > The Apelin-APLNR axis is positioned as a context-dependent regulator of endothelial function and a promising therapeutic target in cardiovascular, pulmonary, and inflammatory diseases.
Key Findings
- The Apelin-APLNR pathway is critical for vascular development and maintaining endothelial homeostasis.
- APLNR is highly enriched in endothelial cells, integrating developmental, mechanical, hypoxic, and inflammatory signals.
- Apelin and Elabela guide angiogenic patterning and support endothelial nitric oxide production and vascular stability.
- Dysregulation of the apelinergic system contributes to hypertension, cardiac remodeling, and pulmonary vascular injury.
- Restoring apelinergic signaling improves endothelial barrier function and mitigates fibrotic/ischemic damage.
Why It Matters
This comprehensive review underscores the Apelin-APLNR pathway as a multifaceted therapeutic target, offering new avenues for treating conditions driven by endothelial dysfunction. For peptide users and biohackers, it highlights the potential of Apelin analogs or APLNR agonists to support vascular health, improve tissue adaptation to stress, and mitigate inflammation. While native Apelin has a short half-life, the emergence of stabilized analogs suggests a path toward more clinically viable protocols. This research indicates that targeting this pathway could lead to novel interventions for cardiovascular, pulmonary, and inflammatory diseases, moving beyond current symptomatic treatments to address underlying endothelial pathology.
apelin
elabela
aplnr
endothelial-function
vascular-remodeling
inflammation